FDA (Drugs) recall action 70452

Attix Pharmaceuticals recalled 470 products on 2015-04-29

The FDA (Drugs) publishes a recall like this one as 470 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 470 pages.

Products: 470
Announced: 2015-04-29
Critical: 0
Units: 2,350

Why these products were recalled

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Stability Data Does Not Support Expiry: All lots of all products repackaged and distributed between 01/05/12 through 02/12/15 are being recalled because they were repackaged without data to support the printed expiry date.

The agency’s own wording, quoted from the enforcement report.

The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.

101–125 of 470

SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Pantoprazole Sodium Monohydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Pantoprazole Sodium Monohydrate repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Pantoprazole Sodium Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Calcium Sulfate Hemihydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Calcium Sulfate Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Calcium Sulfate Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Estradiol (Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Estradiol (Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Levocetirizine Dihydrochloride Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Levocetirizine Dihydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Levocetirizine Dihydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Clonidine HCl Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Clonidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Clonidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Etoposide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Etoposide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Etoposide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Ophthalmic Grade) because it was repackaged in a facility with penicillin products, posing a cross-contamination risk.
Product
Hyaluronic Acid Sodium Salt (Ophthalmic Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Cyclophosphamide Monohydrate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Cyclophosphamide Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Cyclophosphamide Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Phenolphthalein Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Phenolphthalein active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Phenolphthalein active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Ethinyl Estradiol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Ethinyl Estradiol active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Ethinyl Estradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Proparacaine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Proparacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Proparacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls 5-Aminolevulinic Acid Hydrochloride Due to Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling 5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Etidronate Disodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Etidronate Disodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Etidronate Disodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Exemestane API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Exemestane active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed nationwide to compounding pharmacies and research organizations.
Product
Exemestane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Ondansetron HCl Dihydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Ondansetron HCl Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Ondansetron HCl Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls EDTA Dipotassium Magnesium Salt Dihydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Halobetasol Propionate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Halobetasol Propionate active ingredient due to potential penicillin cross-contamination during repackaging.
Product
Halobetasol Propionate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Ammonium Tetrathiomolybdate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Ammonium Tetrathiomolybdate active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Ammonium Tetrathiomolybdate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
ModerateFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Homatropine Methylbromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Homatropine Methylbromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Homatropine Methylbromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Belladonna Extract Powder Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Belladonna Extract Powder because it was repackaged in a facility with penicillin products without adequate separation, creating a risk of cross-contamination.
Product
Belladonna Extract Powder active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Pioglitazone HCl Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Pioglitazone HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Pioglitazone HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Pancuronium Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pancuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Pancuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Gabapentin API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Gabapentin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Gabapentin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Nevirapine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Nevirapine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Nevirapine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states